An Increased Anticholinergic Drug Burden Index Score Negatively Affect Nutritional Status in Older Patients Without Dementia

Esra Ates Bulut 1, Neziha Erken 2, Derya Kaya 2, Fatma Sena Dost 2 and Ahmet Turan Isik 2*

1 Department of Geriatric Medicine, Adana City Training and Research Hospital, Adana, Turkey, 2 Unit for Aging Brain and Dementia, Department of Geriatric Medicine, Faculty of Medicine, Dokuz Eylul University, Izmir, Turkey

Introduction/Aim: Anticholinergic drugs, which have severe central and peripheric side effects, are frequently prescribed to older adults. Increased anticholinergic drug burden is associated with poor physical and cognitive functions. On the other side, the impact of anticholinergics on nutritional status is not elaborated in the literature. Therefore, this study was aimed to investigate the effect of the anticholinergic burden on nutrition.

Materials and Methods: Patients who underwent comprehensive geriatric assessment (CGA) 6 months apart were included in the study. Patients diagnosed with dementia were excluded because of the difference in the course of cognition, physical performance and nutrition. Nutritional status and global cognition were evaluated using Mini Nutritional Assessment-short form (MNA-SF), Mini-Mental State Examination (MMSE). Anticholinergic drug burden was assessed with the Drug Burden Index (DBI), enabling a precise dose-related cumulative exposure. Patients were divided into three groups according to DBI score: 0, no DBI exposure; 0–1, low risk; and ≥1, high risk. Regression analysis was performed to show the relationship between the difference in CGA parameters and the change in DBI score at the sixth month.

Results: A total of 423 patients were included in the study. Participants’ mean age was 79.40 ± 7.50, and 68.6% were female. The DBI 0 score group has better MMSE and MNA-SF scores and a lower rate of falls, polypharmacy, malnutrition, and risk of malnutrition in the baseline. Having malnutrition or risk of malnutrition is 2.21 times higher for every one-unit increase in DBI score. Additionally, during the 6-month follow-up, increased DBI score was associated with decreased MNA-SF and MMSE score, albumin.

Conclusions: The harmful effects of anticholinergics may be prevented because anticholinergic activity is a potentially reversible factor. Therefore, reducing exposure to drugs with anticholinergic activity has particular importance in geriatric practice.

Keywords: anticholinergic activity, cognitive functions, drug burden index, malnutrition, older adults
INTRODUCTION

Older adults are vulnerable to adverse drug reactions and drug-drug interactions because they frequently experience multiple systemic diseases, leading to multiple drug use. Hence, polypharmacy is a significant concern in the management of older patients, and several tools have been developed to review medications, such as Beers Criteria (1), STOPP (Screening Tool of Older Persons’ Prescriptions) and START (Screening Tool to Alert to Right Treatment) criteria (2). Basically, anticholinergic effect determines the safety of the drugs. Anticholinergics inhibit acetylcholine action, which has a crucial role in the regulation of several central and peripheral nervous system functions. Significant anticholinergic effects include dry mouth, constipation, tachycardia, urinary retention, drowsiness, and confusion (3).

Mainly, immobilization, urinary incontinence, neurologic and psychiatric comorbidities (dementia, depression, Parkinson’s disease, epilepsy) were reported as the most significant risk factors for the anticholinergic prescription (4). This group is also at risk of malnutrition. Due to the effects on gastrointestinal motility and secretions, as well as sedative potency, anticholinergics were reported to be related to gait imbalance, dysphagia, delirium (5, 6). A dry mouth may cause difficulty in swallowing, and decreased gastric motility and constipation may contribute to satiety and anorexia. Drowsiness and confusion may cause dehydration, swallowing problems, and aspiration (5), each of which poses a severe risk for malnutrition.

Moreover, older adults are more susceptible to anticholinergic agents because of physiological and pathological changes with aging, including decreased physiological reserve, pharmacodynamic and pharmacokinetic alterations. The anticholinergic burden is termed the cumulative effect of anticholinergic agents and reported as a predictor of cognitive decline, poorer physical performance, falls, and even mortality (7–11). Currently, the optimal scale has not been determined to qualify total anticholinergic drug burden (12). The Drug Burden Index (DBI) is one of the most commonly used validated risk assessment scales to estimate cumulative exposure to anticholinergic medications (13). Additionally, the DBI enables dose-related measurement of each drug and offers an extensive evaluation of several drug classes. Accumulating evidence indicates DBI is a useful indicator of adverse health outcomes and functionality in older adults (14, 15).

Many studies have investigated the relationship between anticholinergic drug burden and cognitive, physical functions. However, the information about the impact of anticholinergics on the nutritional status is limited. We aimed to show the association between DBI score and malnutrition in older adults.

MATERIALS AND METHODS

Patients and Procedures

The records of patients who applied to the geriatric outpatient clinic between January 2017 and March 2020 were retrospectively reviewed. A total of 1,805 patients’ files were screened. Patients who were older than 65 years old and underwent comprehensive geriatric assessment (CGA) (16) two times at 6-month intervals were included in the study. The number of patients who were evaluated twice at the end of 6 months was 811. Exclusion criteria were determined as a severe illness that may impair general health status during the follow-up period, such as acute coronary syndrome, sepsis, acute renal failure, gastrointestinal bleeding, and diagnosis of cancer, immobility, substance and alcohol abuse. Additionally, patients diagnosed with major neurocognitive disorders, including Alzheimer’s disease, vascular dementia, Lewy body dementia, and frontotemporal dementia, which cause progressive deterioration of cognitive domains, were excluded from the study because many medications used in the treatment of those patients, including antipsychotics, sedatives, and antidepressants, also increase DBI scores, and the trajectory of dementia differs in functionality, cognition, nutritional status from cognitive intact older adults. As a result, a total of 423 patients, who did not have exclusion criteria and whose records were eligible, were included in the study.

The study was designed as a retrospective observational cohort study. The primary outcome was defined to show the difference of nutritional parameters including Mini-Nutritional Assessment short-form, weight, albumin between patient groups with increased or decreased DBI score at the end of 6 months, and secondary outcomes were global cognitive performance and functionality.

The investigation was conformed to the Declaration of Helsinki and approved by the local ethics committee.

Comprehensive Geriatric Assessment and Laboratory Measurements

Detailed medication history (including dosage and duration), sociodemographic characteristics, chronic systemic diseases, comprehensive geriatric assessment parameters including Mini-Mental State Examination (MMSE), Geriatric Depression Scale (GDS) (17), Basic (Barthel) and Instrumental (Lawton) Activities of Daily Living (RADL and IADL), Mini-Nutritional Assessment short-form (MNA-SF) were obtained from records of the patients. Falls history in the last year was recorded. Dementia and depression were diagnosed according to the Diagnostic and Statistical Manual of Mental Disorders Fifth Edition (DSM-5) criteria. Comorbidity scores of the patients were calculated using the Charlson Comorbidity Index. Polypharmacy was determined as concurrent five or more drug usage (18). Urinary incontinence was considered positive in having involuntary urinary leakage in the last 3 months except for urinary tract infection (18). Chronic non-cancer pain is accepted as lasting beyond the expected healing time or at least 3–6 months (19).

Laboratory tests including hemogram, albumin, 25-hydroxy vitamin D, vitamin B12, low-density lipoprotein (LDL), high-density lipoprotein (HDL), estimated glomerular filtration rate according to Modification of Diet in Renal Disease (MDRD) Study equation (20) were evaluated.
Drug Burden Index and Anticholinergic Risk Groups

DBI is calculated for each regularly used drug using a formula calculating the ratio between the prescribed daily dose and the sum of the dose that gives 50% of the maximal effect and the prescribed dose. The total score was achieved by summing the score of each sedative drug separately (21). The calculation was carried out by the web portal software program “Anticholinergic Burden Calculator” (www.anticholinergicscales.es/) (22). The main drug classes that were evaluated for their anticholinergic drug burden were antihistamines, benzodiazepines, antipsychotics, selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), alpha blockers, metoclopramide, bladder antimuscarinics and muscle relaxants. Scores of the participants were calculated as a continuous variable. Accordingly, three groups were identified: DBI score 0 (no DBI exposure), DBI score 0–1 (low), and DBI score ≥1 (high) (23).

Nutritional Assessment and Malnutrition

The patients were grouped according to MNA-SF scores: malnourished (<7 points), risk of malnutrition (8–11 points), or well-nourished (≥12 points) (24). Nutritional assessment was conducted twice apart 6-months to the patients such as other CGA parameters.

Statistical Analysis

Categorical variables were evaluated with chi-square tests. Normal distribution was checked using the Kolmogorov-Smirnov test. Categorical and continuous variables are expressed as percentages (%) and mean ± standard deviations, respectively.

RESULTS

A total of 423 patients were included in the study. Participants’ mean age was 79.40 ± 7.50, and 68.6% were female. When the patients were divided into three according to DBI risk score in the baseline, 225 patients had DBI 0 score, 135 had low risk, and 33 had high risk. Age, sex, and educational status were similar between the groups. Patients diagnosed with diabetes mellitus and depression were common in the low and high-risk groups (p < 0.05). Compared with patients with a DBI score 0, those in the risk groups had a higher rate of polypharmacy, falls and
TABLE 1 | Patients’ characteristics according to basal DBI risk status.

| DBI score | Zero (0) | Low risk (0-1) | High risk (≥1) | p  
|-----------|----------|----------------|----------------|-----
| n:        | 225      | 135            | 33             |     
|           |          |                |                |     
| Demographics |          |                |                |     
| Sex (female%)  | 68.2     | 68.9           | 69.7           | 0.98 
| Marital status (married) (%) | 78.88 ± 7.43 | 80.51 ± 7.44 | 78.87 ± 8.03 | 0.08  
| Education (years) | 8.17 ± 4.93 | 8.08 ± 4.80 | 6.38 ± 4.81 | 0.16  
| Sex (female%)  | 68.2     | 68.9           | 69.7           | 0.98 
| Marital status (married) (%) | 78.88 ± 7.43 | 80.51 ± 7.44 | 78.87 ± 8.03 | 0.08  
| Education (years) | 8.17 ± 4.93 | 8.08 ± 4.80 | 6.38 ± 4.81 | 0.16  
| Comorbidities (%) |          |                |                |     
| Depression | 22.4     | 42.2           | 48.5           | <0.01 
| Diabetes mellitus | 23.5     | 28.9           | 54.5           | <0.01  
| Hypertension | 65.9     | 71.1           | 72.7           | 0.48  
| Ischemic cardiac disease | 14.5     | 17.8           | 21.9           | 0.46  
| Charlson comorbidity index | 0.82 ± 1.06 | 1.18± 1.38 | 1.27 ± 1.28 | 0.01  
| Geriatric syndromes (%) |          |                |                |     
| Polypharmacy | 35.3     | 65.2           | 87.9           | <0.01 
| Urinary Incontinence | 38.8     | 40.0           | 39.4           | 0.97  
| Falls | 21.2     | 34.8           | 42.4           | <0.01  
| Pain | 46.6     | 50.7           | 59.4           | 0.34  
| Comprehensive geriatric assessment parameters |          |                |                |     
| MMSE | 27.02 ± 3.28 | 25.87 ± 4.22 | 24.50 ± 4.96 | 0.01  
| GDS | 2.52 ± 3.12 | 3.15 ± 3.02 | 5.76 ± 4.43 | <0.01  
| MNA-SF | 12.49 ± 1.96 | 11.85 ± 2.28 | 11.70 ± 2.08 | <0.01  
| BADL | 96.08 ± 6.95 | 93.70 ± 9.75 | 88.42 ± 17.20 | <0.01  
| IADL | 19.99 ± 4.04 | 18.80 ± 5.00 | 17.06 ± 6.15 | <0.01  
| Laboratory values |          |                |                |     
| Hemoglobin (g/dL) | 13.03 ± 1.48 | 12.73 ± 1.50 | 12.51 ± 1.52 | 0.02  
| Albumin (mg/dL) | 4.19 ± 0.27 | 4.07 ± 0.37 | 4.09 ± 0.41 | 0.02  
| HDL (mg/dL) | 58.63 ± 13.95 | 55.95 ± 13.65 | 52.11 ± 14.11 | 0.06  
| LDL (mg/dL) | 133.85 ± 37.98 | 133.95 ± 41.44 | 118.64 ± 34.40 | 0.27  
| MDRD (mL/dk) | 75.69 ± 18.01 | 72.67 ± 19.71 | 73.44 ± 17.65 | 0.32  
| Vitamin D (ng/mL) | 20.72 ± 14.42 | 19.25 ± 13.08 | 22.62 ± 15.60 | 0.27  
| Vitamin B12 (pg/mL) | 447.01 ± 300.19 | 537.97 ± 408.66 | 485.68 ± 375.56 | 0.25  

MDRD, Modification of Diet in Renal Disease; MMSE, Mini Mental State Examination; GDS, Geriatric Depression Scale (0–15); MNA-SF, Mini Nutritional Assessment (0–12); BADL, Basic Activities of Daily Living (0–100); IADL, Instrumental Activities of Daily Living (0–23). Bold values denote statistical significance at the p < 0.05 level.

Malnutrition, and higher Charlson Comorbidity Score, whereas lower baseline albumin, and hemoglobin levels. Moreover, the DBI 0 score group has the best values in regards to CGA parameters. Table 1 summarizes the baseline characteristics of the patients.

According to the MNA-SF scores, normal nutritional status was statistically higher in the patients with DBI 0 score (p < 0.01) compared to both low and high DBI risk groups in the baseline. The total rate of malnutrition and malnutrition risk was similar in the DBI low and high risk groups. Figure 2 shows the nutritional status of the groups in the baseline.

When the relationship between nutritional status and DBI score and number of drugs routinely used was evaluated, it was found that both parameters were associated with increased malnutrition and malnutrition risk. However, the DBI score was found to have a more substantial contribution to the risk.

The odds of having malnutrition or risk of malnutrition is 2.21 times greater for every one-unit increase in DBI score. The anticholinergic characteristics of drugs is more substantial impact on the nutritional status instead of total number of drugs used. Table 2 shows the relationship between nutritional status and drug number, and DBI scores.

Accordingly, the follow-up data of 414 patients whose DBI score of 0 from the beginning or DBI score changed was analyzed. According to the change in DBI score, three groups were obtained: no DBI exposure from the beginning, decreased DBI scores, and increased DBI scores. Delta scores did not differ between the three groups (Table 3).

When the change in CGA parameters was analyzed, it was shown that every one-unit increase in the DBI score decreases the positive change in nutrition score by 37%. Similarly, the MMSE score decreases by almost 40%. Moreover, a one-unit increase
in DBI score also associated with the decrease in albumin level (Table 4).

**DISCUSSION**

The study shows that increased DBI scores are related to geriatric syndromes such as falls, malnutrition, and polypharmacy. Additionally, an increase in the DBI score during the sixth-month follow-up duration is associated with the lower cognitive and nutritional status in cognitively intact older patients. Notably, the DBI score seems more influential on nutritional status than the total drug number.

Parkinson’s disease, cognitive impairment, genitourinary conditions, depression, and institutionalization are major predictors of the higher use of anticholinergic drugs. Although older patients are more vulnerable to the side effects of these drugs, anticholinergic drugs are frequently prescribed to older adults. Anticholinergic use prevalence is reported from 22.8 to 55.9% in community-dwelling older adults (12) and more than 79% of inpatients (25). Several tools and guidelines designed to review drugs accept anticholinergic drugs as potentially inappropriate drugs (26). Higher anticholinergic burden is blamed for adverse health outcomes, such as cognitive decline, poorer physical performance, falls, longer length of stay and mortality (11, 12, 27–29). The present study results also support the negative effect of the anticholinergic burden on cognitive functions. The anticholinergic effects on the central nervous system (CNS) areas responsible for movement control, balance, learning, and memory were blamed for the worse outcomes. On the other hand, it is a debate whether increased anticholinergic burden leads to worse outcomes or whether the diseases being treated by the anticholinergic drugs, including neurodegenerative diseases, are responsible for the decline in cognition and physical performance. Therefore, we excluded patients diagnosed with dementia to mitigate the confounding effect of the underlying condition on the course of patients.

Moreover, malnutrition and risk of malnutrition are significant conditions that are reported between 10 and 40% in community-dwelling older adults (30). Malnutrition also causes serious health consequences such as falls, osteoporosis, orthostatic hypotension, and mortality (31). Many risk factors, including increased age, dementia, decreased social support, dysphagia, depression, polypharmacy, anorexia were specified to develop inadequate nutrition (32). However, to our knowledge, the relationship between malnutrition and anticholinergic drug burden is not elaborated in literature so far. In this longitudinal study, it was observed that increased anticholinergic...
load was associated with worsening nutritional status and decreased albumin level which is also an indirect marker for malnutrition (33). The impact of the anticholinergic burden on nutrition may be explained by the gastrointestinal system and cognitive effects of anticholinergic agents (5). One of the well-known peripheral side effects, dry mouth (xerostomia), leads to poor dentition, altered taste, difficulty in deglutition, and digestion (34). Dysphagia makes the development of aspiration more likely and causes serious complications such as aspiration pneumonia. Reduced gastrointestinal motility and secretion contribute to constipation, anorexia, and early satiety. Additionally, central side effects including cognitive impairment, drowsiness, confusion, poor attention, restlessness may lead to swallowing difficulties, dehydration, and aspiration. Sedative effects of the drugs contribute to anorexia (3).

Although the best scale evaluates the cholinergic load is not determined, DBI is a feasible and validated scale (29, 35). Using the DBI offers an assessment of anticholinergic activity with a dose-response model. Thus, the exposure of drugs being administered to a patient could precisely be estimated. Previous studies support that DBI is related to worse cognitive and physical function (6, 36–39). Accordingly, DBI is selected in the present study to evaluate the anticholinergic burden. High and low exposure risk groups were identified to show the impact of cholinergic burden change on nutrition, cognition, and functionality in the longitudinal analysis. Increased DBI scores negatively influence cognitive and nutritional scores.
The study has many strength aspects. First, the anticholinergic burden was evaluated based on medications at the baseline, and changes take into consideration during the 6-month follow-up. Second, all patients were examined in a detailed manner with CGA, including functionality, global cognition, nutritional status, and most of the geriatric syndromes. Third, the study has a large sample size, and a validated scale was used to quantify the anticholinergic burden objectively. Fourth, to the best of our knowledge, the study is the first longitudinal study investigating the relationship between DBI rated anticholinergic burden and nutritional status in older adults. On the contrary, there are limited features of the study. Although patients with major neurocognitive disorders were excluded from the study, we could not adjust all confounding factors such as depression, increasing the risk of exposure to drugs with anticholinergic properties. In addition, the follow-up duration may be shorter to assess long-term effects of anticholinergic drugs. Thus, larger size, long term follow-up studies are needed to clarify the complex relationship between anticholinergic burden and nutritional status in older adults.

CONCLUSION

The serious adverse effects may be prevented because the anticholinergic activity is a potentially reversible factor. Therefore, reducing exposure to drugs with anticholinergic activity has particular importance in geriatric practice. Withdrawal of unnecessary drugs (to avoid potential drug interactions) or decrease anticholinergic agents are the main strategies that should be implemented in clinical settings to improve nutritional and cognitive outcomes in older adults. Such tiny interventions provide essential contributions in the management of geriatric cases. Further evidence is warranted to explain the mechanisms that effects of anticholinergic medications on nutrition.

DATA AVAILABILITY STATEMENT

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by Non-interventional Studies Ethics Committee of Dokuz Eylül University. The patients/participants provided their written informed consent to participate in this study.

AUTHOR CONTRIBUTIONS

AI and EA made the study concept and design. NE and FD helped acquisition of data. EA and DK performed analysis, critical revision of the manuscript for important intellectual interpretation of data, and draft the manuscript. AI established the study concept and design. NE and FD helped acquisition of data. EA and DK performed analysis, critical revision of the manuscript for important intellectual content. All authors contributed to the article and approved the submitted version.

REFERENCES

1. American Geriatrics Society 2019 updated AGS beers criteria® for potentially inappropriate medication use in older adults. J Am Geriatr Soc. (2019) 67:674–94. doi: 10.1111/jgs.15767
2. O’Mahony D, O’Sullivan D, Byrne S, O’Connor MN, Ryan C, Gallagher P. STOPP/START criteria for potentially inappropriate prescribing in older people: version 2. Age Aging. (2015) 44:213–8. doi: 10.1093/ageing/afu145
3. Feinberg M. The problems of anticholinergic adverse effects in older patients. Drugs Aging. (1993) 3:335–48. doi: 10.2165/00002512-199303040-00004
4. Wawruch M, Macugova A, Kosikova L, Luha J, Dukat A, Murin J, et al. The use of medications with anticholinergic properties and risk factors for their use in hospitalised elderly patients. Pharmacoeconomiet Drug Saf. (2012) 21:170–6. doi: 10.1002/pds.2169
5. Castejón-Hernández S, Latorre-Valbbona N, Molist-Brunet N, Cubi-Montanyà D, Espaullella-Panicot J. Association between anticholinergic burden and oropharyngeal dysphagia among hospitalized older adults. Aging Clin Exp Res. (2020) 33:1981–5. doi: 10.1007/s40520-020-01707-9
6. Wilson NM, Hilmer SN, March LM, Cameron ID, Lord SR, Seibel MJ, et al. Associations between drug burden index and falls in older people in residential aged care. J Am Geriatr Soc. (2011) 59:875–80. doi: 10.1111/j.1532-5415.2011.03386.x
7. Fox C, Smith T, Maidment I, Chan WY, Rua N, Myint PK, et al. Effect of medications with anti-cholinergic properties on cognitive function, delirium, physical function and mortality: a systematic review. Age Aging. (2014) 43:604–15. doi: 10.1093/ageing/aft096
8. Bishara D, Perera G, Harwood D, Taylor D, Sauer J, Stewart R, et al. The anticholinergic effect on cognition (AEC) scale-Associations with mortality, hospitalisation and cognitive decline following dementia diagnosis. Int J Geriatr Psychiatry. (2020) 35:1069–77. doi: 10.1002/gps.5330
9. Cao YJ, Mager DE, Simonsick EM, Hilmer SN, Ling SM, Windham BG, et al. Physical and cognitive performance and burden of anticholinergics, sedatives, and ACE inhibitors in older women. Clin Pharmacol Ther. (2008) 83:422–9. doi: 10.1038/sj.clpt.6100303
10. Hilmer SN, Mager DE, Simonsick EM, Ling SM, Windham BG, Harris TB, et al. Drug burden index score and functional decline in older people. Am J Med. (2009) 122:1142–9.e1–2. doi: 10.1016/j.amjmed.2009.02.021
11. Stewart C, Yrjana K, Kishor M, Soiza RL, Taylor-Rowan M, Quinn TJ, et al. Anticholinergic burden measures predict older people’s physical function and quality of life: a systematic review. J Am Med Direct Assoc. (2021) 22:56–64. doi: 10.1016/j.jamda.2020.05.065
12. Salahudeen MS, Duffull SB, Nishtala PS. Anticholinergic burden quantified by anticholinergic risk scales and adverse outcomes in older people: a systematic review. BMC Geriatr. (2015) 15:31. doi: 10.1186/s12877-015-0029-9
13. Hilmer SN, Mager DE, Simonsick EM, Cao Y, Ling SM, Windham BG, et al. A drug burden index to define the functional burden of medications in older people. Arch Intern Med. (2007) 167:781–7. doi: 10.1001/archinte.167.8.781
14. Salahudeen MS, Hilmer SN, Nishtala PS. Comparison of anticholinergic risk scales and associations with adverse health outcomes in older people. J Am Geriatr Soc. (2015) 63:85–90. doi: 10.1111/jgs.13206
15. Okudur SK, Dokuzlar O, Aydin AE, Kocyigit SE, Soysal P, Isik AT. The evaluation of relationship between polypharmacy and anticholinergic burden scales. Northern Clin Istanbul. (2021) 8:139–44. doi: 10.14744/nci.2020.17136
16. Unutmaoz GD, Soysal P, Tuven B, Isik AT. Costs of medication in older patients: before and after comprehensive geriatric assessment. Clin Interv Aging. (2018) 13:607–13. doi: 10.2147/CIA.S159966
17. Durmaz B, Soysal P, Ellidokuz H, Isik AT. Validity and reliability of geriatric depression scale-15 (short form) in Turkish older adults. Northern Clin Istanbul. (2018) 5:216–20. doi: 10.14744/nci.2017.85047
18. Ates Bulut E, Soysal P, Isik AT. Frequency and coincidence of geriatric syndromes according to age groups: single-center experience.
in Turkey between 2013 and 2017. Clin Interv Aging. (2018) 13:1899–905. doi: 10.2147/CIA.S180281

19. Pharmacological management of persistent pain in older persons. J Am Geriatr Soc. (2009) 57:1331–46. doi: 10.1111/j.1532-5415.2009.02376.x

20. Levey AS, Greco J, Greene T, Stevens LA, Zhang YL, Hendriksen S, et al. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Inter Med. (2006) 145:247–54. doi: 10.7326/0003-4819-145-4-200608150-00004

21. Wouters H, Hilmer SN, Twisk J, Teichert M, Van Der Meer HG, Van Hout HPJ, et al. Drug burden index and cognitive and physical function in aged care residents: a longitudinal study. J Am Med Directors Assoc. (2020) 21:1086–92.e1. doi: 10.1016/j.jamda.2020.05.037

22. Villalta-Moreno Á, Alfaro-Lara ER, Sánchez-Fidalgo S, Nieto-Martín MD, Santos-Ramos B. Development of the anticholinergic burden calculator web tool. Farm Hosp. (2017) 41:647–8. doi: 10.1136/ehp-harm-2017-000 640.421

23. Gnjidic D, Hilmer SN, Hartkainen S, Tolppanen AM, Taipale H, Koponen M, et al. Impact of high risk drug use on hospitalization and mortality in older people with and without Alzheimer's disease: a national population cohort study. PLoS ONE. (2014) 9:e83224. doi: 10.1371/journal.pone.0083224

24. Rubenstein LZ, Harker JO, Salva A, Guigoz Y, Vellas B. Screening for undernourishment in geriatric practice: developing the short-form mini-nutritional assessment (MNA-SF). J Gerontol Series A Biol Sci Med Sci. (2001) 56:M366–72. doi: 10.1093/gerona/56.6.M366

25. Pasina L, Colzani L, Cortesi L, Tettamanti M, Zambon A, Nobili A, et al. Relation between delirium and anticholinergic drug burden in a cohort of hospitalized older patients: an observational study. Drugs Aging. (2019) 36:85–91. doi: 10.1007/s40266-018-0612-9

26. Idil E, Aydin AE, Ates Bulut E, Isik AT. Rationally decreasing the number of drugs seems to be a useful therapeutic approach in older adults with or without Alzheimer’s disease: a national population cohort study. PLoS ONE. (2014) 9:e83224. doi: 10.1371/journal.pone.0083224

27. Ruxton K, Woodman RJ, Mangoni AA. Drugs with anticholinergic effects and cognitive impairment, falls and all-cause mortality in older adults: a systematic review and meta-analysis. Ann Intern Med. (2016) 7:507–22. doi: 10.3945/an.115.011254

28. Levey AS, Coresh J, Greene T, Stevens LA, Zhang YL, Hendriksen S, et al. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Inter Med. (2006) 145:247–54. doi: 10.7326/0003-4819-145-4-200608150-00004

29. Welsh TJ, van der Wardt V, Ojo G, Gordon AL, Gladman JR. Anticholinergic burden tools/scales and adverse outcomes in different clinical settings: a systematic review of reviews. Drugs Aging. (2018) 35:523–38. doi: 10.1007/s40266-018-0549-z

30. Koçyigit SE, Soysal P, Ates Bulut E, Isik AT. Malnutrition and Malnutrition risk can be associated with systolic orthostatic hypotension in older adults. J Nutr Health Aging. (2018) 22:928–33. doi: 10.1007/s12603-018-1032-6

31. Koçyigit SE, Ates Bulut E, Aydin AE, Isik AT. Improvement of nutritional status enhances cognitive and physical functions in older adults with orthostatic hypotension. Nutrition. (2021) 90:111261. doi: 10.1016/j.nut.2021.111261

32. Favar-Moreira NC, Krausch-Hofmann S, Matthys C, Vereecken C, Vanhuwaert E, Declercq A, et al. Risk factors for malnutrition in older adults: a systematic review of the literature based on longitudinal data. Adv Nutr. (2016) 7:507–22. doi: 10.3945/an.115.011254

33. Cabreroiz S, Cuadras D, Gomez-Busto E, Artaza-Artabe I, Marin-Ciancas F, Malafarina V. Serum albumin and health in older people: review and meta analysis. Maturitas. (2015) 81:17–27. doi: 10.1016/j.maturitas.2015.02.009

34. Lavrador M, Cabral AC, Figueiredo IV, Veríssimo MT, Castel-Branco MM, Fernandez-Llimos F. Size of the associations between anticholinergic burden tool scores and adverse outcomes in older patients. Int J Clin Pharm. (2021) 43:128–36. doi: 10.1007/s11096-020-01117-x

35. Kouladjian L, Gnjidic D, Chen TF, Mangoni AA, Hilmer SN. Drug Burden Index in older adults: theoretical and practical issues. Clin Interv Aging. (2014) 9:1503–15. doi: 10.2147/CIA.S66660

36. Wilson NM, Hilmer SN, March LM, Cameron ID, Lord SR, Seibel MJ, et al. Associations between drug burden index and physical function in older people in residential aged care facilities. Age Ageing. (2010) 39:503–7. doi: 10.1093/ageing/afq053

37. Nishita PS, Narayan SW, Wang T, Hilmer SN. Associations of drug burden index with falls, general practitioner visits, and mortality in older people. Pharmacoepidemiol Drug Safety. (2014) 23:753–8. doi: 10.1002/pds.3624

38. Nishita PS, Allore H, Han L, Jamieon HA, Hilmer SN, Chyso TY. Impact of anticholinergic burden on cognitive performance: a cohort study of community-dwelling older adults. J Am Med Directors Assoc. (2020) 21:1357–8.e3. doi: 10.1016/j.jamda.2020.03.027

39. Gnjidic D, Le Couteur DG, Abernethy DR, Hilmer SN. Drug burden index and beers criteria: impact on functional outcomes in older people living in self-care retirement villages. J Clin Pharmacol. (2012) 52:258–65. doi: 10.1177/00912700124395591

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Ates Bulut, Erken, Kaya, Dost and Isik. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.